Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP913880.RAWWR_hYZHuph6RVCfDnYdi6udnw1-eiAJFqFTVbLpDOc130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP913880.RAWWR_hYZHuph6RVCfDnYdi6udnw1-eiAJFqFTVbLpDOc130_provenance.
• NP914068.RARGWTjrR2lR8bVOKLDvG4Lw10kD99X8TtmGQDnJhoOM8130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914068.RARGWTjrR2lR8bVOKLDvG4Lw10kD99X8TtmGQDnJhoOM8130_provenance.
• NP286374.RAagidXbDyBshSfx-PxrzUmZ_SeWei8qArAJDpSalgpbs130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP286374.RAagidXbDyBshSfx-PxrzUmZ_SeWei8qArAJDpSalgpbs130_provenance.
• NP475200.RAfUcrM8HkqBiLF8HBfQMZuovWtpaR1MaQ9I6sDP68pY0130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP475200.RAfUcrM8HkqBiLF8HBfQMZuovWtpaR1MaQ9I6sDP68pY0130_provenance.
• NP286305.RAvUvawZB6rN_vGfKuhF8vmf3ltbsiWH0I_FMIsM8aPts130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP286305.RAvUvawZB6rN_vGfKuhF8vmf3ltbsiWH0I_FMIsM8aPts130_provenance.
• NP978560.RAAWKh17PWoruPl9XBU1dwti6GmbsXjwiJl5-QC9ZLkY8130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978560.RAAWKh17PWoruPl9XBU1dwti6GmbsXjwiJl5-QC9ZLkY8130_provenance.
• NP567295.RAtD7HkcBEpPrOMIUXkTZcPe9lEsZz2exUWrCfz4EayCc130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP567295.RAtD7HkcBEpPrOMIUXkTZcPe9lEsZz2exUWrCfz4EayCc130_provenance.
• NP922470.RAZTEvJneXVFPsuJnD6scIwAQoqItr8h75ybnqQ5DsY-Y130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922470.RAZTEvJneXVFPsuJnD6scIwAQoqItr8h75ybnqQ5DsY-Y130_provenance.
• NP922476.RAYwvJuz94Bxh17LRC2NgNtfKDTNoip5ExvxrGXq6GzMM130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922476.RAYwvJuz94Bxh17LRC2NgNtfKDTNoip5ExvxrGXq6GzMM130_provenance.
• NP922478.RAW_wXj7ZMtYrnTqSa0ndSpDWd_y-bvCKUW-K4H14NsXQ130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922478.RAW_wXj7ZMtYrnTqSa0ndSpDWd_y-bvCKUW-K4H14NsXQ130_provenance.
• NP922484.RAdrG7J1JFJvyKlobvNNTCHBG_m3C_QrbNlS38DTNPosE130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922484.RAdrG7J1JFJvyKlobvNNTCHBG_m3C_QrbNlS38DTNPosE130_provenance.
• NP474932.RAnCQLC0o44uL7M1d5nSvryrNjOs3IMOrOeHKGPfAhUzo130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP474932.RAnCQLC0o44uL7M1d5nSvryrNjOs3IMOrOeHKGPfAhUzo130_provenance.
• NP922480.RAoixba4ziuAvidpeXnNG5etK0iqIVUAUD3lX3N1oHCNo130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922480.RAoixba4ziuAvidpeXnNG5etK0iqIVUAUD3lX3N1oHCNo130_provenance.
• NP474736.RA-vmsr8UOFlDNBwoe7lM2ERbH1luK3aatpl7BaHRcajc130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP474736.RA-vmsr8UOFlDNBwoe7lM2ERbH1luK3aatpl7BaHRcajc130_provenance.
• NP475353.RA3-S7XBN6AMyrvWAMpV7JrXhLC3G0KxDXNk_QqfJSbdw130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP475353.RA3-S7XBN6AMyrvWAMpV7JrXhLC3G0KxDXNk_QqfJSbdw130_provenance.
• NP286379.RA7j2msZAkHwFRmnVy6c_cDilyou8Xgs7xTXXhSQdZGNk130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP286379.RA7j2msZAkHwFRmnVy6c_cDilyou8Xgs7xTXXhSQdZGNk130_provenance.
• NP474917.RAIK4nhOAZcSzC6Bjfor9FN57vHhhzJqnqFQG4nXSJZVc130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP474917.RAIK4nhOAZcSzC6Bjfor9FN57vHhhzJqnqFQG4nXSJZVc130_provenance.
• NP922468.RAG6QSa-cnkpj3foJX-xAocsco1KrZ-ARhI00pdgZsxZ4130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922468.RAG6QSa-cnkpj3foJX-xAocsco1KrZ-ARhI00pdgZsxZ4130_provenance.
• NP922469.RA2KMcPs6sUAtsf3DhIiKS_voIZO6OjmOvX3QeQ86VIQk130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922469.RA2KMcPs6sUAtsf3DhIiKS_voIZO6OjmOvX3QeQ86VIQk130_provenance.
• NP922471.RA1MmXc60lS9ZrUXdCbKAkRKokrWNQPSOk9zWo2RSciVo130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922471.RA1MmXc60lS9ZrUXdCbKAkRKokrWNQPSOk9zWo2RSciVo130_provenance.
• NP922472.RA5TbOKmj1Rn01_TFnE5VBfYypFpRCVUauEK_45grZWtc130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922472.RA5TbOKmj1Rn01_TFnE5VBfYypFpRCVUauEK_45grZWtc130_provenance.
• NP922473.RA8_Ix2OxtI4uV3ymxhSxBi9SkA_FvG343n_AHXoc4tfo130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922473.RA8_Ix2OxtI4uV3ymxhSxBi9SkA_FvG343n_AHXoc4tfo130_provenance.
• NP922474.RA3yG7RXi5FBzCInss3Nb6wbe6aoK7ZWxQc-yquO0EWcY130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922474.RA3yG7RXi5FBzCInss3Nb6wbe6aoK7ZWxQc-yquO0EWcY130_provenance.
• NP922475.RA2y6g4gr00pgczGWV1eyPSgV2SmA0MTERwjJCBoZ65p0130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922475.RA2y6g4gr00pgczGWV1eyPSgV2SmA0MTERwjJCBoZ65p0130_provenance.
• NP922477.RAypKrDR3_BOhCcRnyrvFYi0nBr-HccvhxenpWmdlHLmM130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922477.RAypKrDR3_BOhCcRnyrvFYi0nBr-HccvhxenpWmdlHLmM130_provenance.
• NP922479.RA0U_UuVwGnk4a1c7ikhGOyWv8MfszSH-CTb8PBt8N8KM130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922479.RA0U_UuVwGnk4a1c7ikhGOyWv8MfszSH-CTb8PBt8N8KM130_provenance.
• NP922483.RAxT2KpPjSFCQfLgo88_BFyCgS4jYO_85KZ45hkjsV6II130_assertion description "[We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922483.RAxT2KpPjSFCQfLgo88_BFyCgS4jYO_85KZ45hkjsV6II130_provenance.